More results...
In the four years since I inherited this column, eight states have legalized recreational cannabis, Colorado has decriminalized psilocybin, ibogaine and mescaline for therapeutic use, Mexico and Thailand legalized cannabis,...
After more than 50 years of classification as a dangerous, highly addictive drug with no medical value, the U.S. federal government is changing its stance on cannabis. On April 30,...
There are more than 600 known neurological disorders like Alzheimer’s and Parkinson’s. Over 50 million Americans suffer from them every year, according to the National Institute of Health. Alzheimer’s alone...
Anna Schwabe was studying cannabis genetics for her PhD at Northern Colorado University, investigating whether people could smell genetic differences between cannabis strains. After getting back reports on samples she’d...
President Joe Biden’s State of the Union (SOTU) address was particularly exciting for Americans involved in the cannabis industry. While discussing his goals on things like mental health issues, gun...
In the U.S., 28 million people will suffer from an eating disorder in their lifetime, according to a Harvard study from 2020. Anorexia and bulimia nervosa disorders are the most...
According to the National Institute on Alcoholism and Alcohol Abuse (NIAAA), 62.8% (177 million) of Americans 12 and older used alcohol at least once in 2022. According to the Centers...
Alex Bradshaw has been on a mission to map the genomic diversity of psilocybe for years. He’s been determined to find out when these peculiar mushrooms started producing psilocybin — and...
Employers in the U.S. cannot fire someone for partaking in legal drug or alcohol consumption, so long as it is done off hours and doesn’t affect their performance on the...
There are a lot of rules and restrictions around who can get a concealed carry permit in the U.S. You have to be over 21 years old. In Colorado, you...
MDMA is one step closer to becoming the first FDA-approved psychedelic drug. In October 2023, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced it completed its phase three clinical trial...